CrushSCI.com
157.6Average days
145Median days
35Fastest days
409Longest days
1472025 publications

Paper Review Records

All Paper Review Records

30 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

409 days

Untargeted Metabolomics of Dried Blood Spots for Inherited Metabolic Disorder Classification

Authors
Jan‐Clemens Cremer; Lorenz Waltl; Viktorija Juric; Jakob Koch; Sabine Scholl‐Bürgi; Daniela Karall; Johannes Zschocke; Markus A. KellerShow moreShow less
Affiliations
1. Institute of Human Genetics, Medical University of Innsbruck Innsbruck Austria; 2. Department of Paediatrics I (Inherited Metabolic Disorders) Medical University of Innsbruck Innsbruck AustriaShow moreShow less
Source PDF DOI Publisher page
84 days

Bringing Untargeted Metabolomics to the Clinic: Real‐World Data and Implementation for Screening of Inherited Metabolic Diseases

Authors
D. Augustijn; R. Bonte; M. C. Hagemeijer; J. Bierau; E. H. Jacobs; C. J. Klein‐de Ronde; E. van der Star; D. Y. van Haaften‐Visser; N. C. Peltenburg‐de Jong; C. Debuy; M. van Dijk; D. Vos; G. J. G. Ruijter; S. M. I. GoordenShow moreShow less
Affiliations
1. Centre of Lysosomal and Metabolic Diseases, Department of Clinical Genetics Erasmus Medical Centre Rotterdam the Netherlands; 2. Department of Clinical Chemistry Erasmus MC Rotterdam the Netherlands; 3. Centre of Lysosomal and Metabolic Diseases, Department of Paediatrics Erasmus Medical Centre Rotterdam the Netherlands; 4. Centre of Lysosomal and Metabolic Diseases, Department of Internal Medicine Erasmus Medical Centre Rotterdam the Netherlands; 5. Laboratory Genetic Metabolic Diseases, Department of Laboratory Medicine Amsterdam University Medical Centre Amsterdam the NetherlandsShow moreShow less
Source PDF DOI Publisher page
209 days

Migalastat Versus Enzyme Replacement Therapy in Treatment‐Naïve F abry Disease: Real‐World Evidence From the followME F abry Pathfinders Registry

Authors
Peter Nordbeck; Agnieszka Kopiec; Noemi Hummel; Vera Gielen; Biliana O. Veleva‐Rotse; Alasdair MacCullochShow moreShow less
Affiliations
1. University Hospital Würzburg Würzburg Germany; 2. Certara Krakow Poland; 3. Certara GmbH Lörrach Germany; 4. BioMarin UK Ltd London UK; 5. BioMarin Pharmaceutical Inc. Novato California USAShow moreShow less
Source PDF DOI Publisher page
145 days

Nucleic Acid Therapeutics in Rare Disease: From Precision Medicine to Programmable Platforms

Authors
Tomasz Z. Tomkiewicz; Siyamini Sivananthan; Paul Gissen; Haiyan ZhouShow moreShow less
Affiliations
1. Genetics and Genomic Medicine Research and Teaching Department Great Ormond Street Institute of Child Health, University College London London UK; 2. NIHR Great Ormond Street Hospital Biomedical Research Centre London UKShow moreShow less
Source PDF DOI Publisher page
195 days

Thymidine Kinase 2 Deficiency in the Era of Approved Therapy: From Diagnosis to Evidence Across the Disease Spectrum

Authors
Paloma Martin‐Jimenez; Cristina Domínguez‐GonzálezShow moreShow less
Affiliations
1. Neuromuscular Diseases Unit, Neurology Department Hospital Universitario 12 de Octubre Madrid Spain; 2. Medical‐Surgical Sciences Research, Faculty of Medicine Complutense University Madrid Spain; 3. Mitochondrial and Neuromuscular Research Group ’12 de Octubre’ imas12 Research Institute Madrid Spain; 4. Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid SpainShow moreShow less
Source PDF DOI Publisher page
83 days

Revisiting Inherited Metabolic Diseases ( IMDs ) Through the Lens of Selective Autophagy

Authors
Marianna Maddaluno; Laura Cinque; Viviana Cetrangolo; Chiara De LeonibusShow moreShow less
Affiliations
1. Telethon Institute of Genetics and Medicine (TIGEM) Pozzuoli Italy; 2. Department of Clinical Medicine and Surgery Federico II University Naples Italy; 3. Department of Precision Medicine University of Campania “Luigi Vanvitelli” Naples Italy; 4. Department of Health Sciences University of Basilicata Potenza ItalyShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does JOURNAL OF INHERITED METABOLIC DISEASE take to review a manuscript?

As of 2026-11-17, CrushSCI has 30 complete review records for JOURNAL OF INHERITED METABOLIC DISEASE. The fastest paper went from submission to acceptance in 35 days (Consensus Guidelines for Diagnosis and Management of Pyruvate Dehydrogenase Complex Deficiency, received 2026-05-29, accepted 2026-07-03); the slowest took 409 days. The average is 157.6 days and the median is 145 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.